Washington, D.C. (March 24, 2014) — America’s biopharmaceutical research companies currently are developing 37 innovative new medicines to help the estimated 10 million people worldwide who are living with Parkinson’s disease. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 23 for Parkinson’s disease, 11 for related conditions and 3 diagnostics, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).Continue reading→